The Therapeutic Potential Of GLP-1 Receptor Agonists: A Comprehensive Overview
![]() |
| GLP-1 Receptor Agonists |
GLP-1 Receptor Agonist RAs exert their effects by binding to and activating the GLP-1 receptor
on pancreatic beta cells, adipocytes, and other tissues. Once bound, these
medications initiate a cascade of intracellular events that promote
glucose-dependent insulin secretion and inhibit glucagon release. This
glucose-dependent action minimizes the risk of hypoglycemia. Furthermore, GLP-1
RAs slow down gastric emptying, reducing postprandial glucose excursions. By
acting on the central nervous system, they enhance satiety, leading to
decreased food intake and potential weight loss.
The
Global
GLP-1 Receptor Agonist Market Is Estimated To Be Valued At US$
12,720.6 Million In 2021 And
Is Expected To Exhibit A CAGR Of 6.1% Over The Forecast Period (2021-2028).
Numerous clinical trials have demonstrated the efficacy of GLP-1 Receptor Agonist RAs in improving
glycemic control in patients with T2DM. These agents have been shown to reduce
hemoglobin A1c (HbA1c) levels by 0.5% to 1.5%. GLP-1 RAs can be used as
monotherapy, dual therapy in combination with other oral antidiabetic agents,
or as an adjunct to insulin therapy. Their glucose-lowering effects are
particularly pronounced in patients with inadequate glycemic control despite
maximal oral antidiabetic therapy.
In addition to glycemic control, GLP-1 RAs have demonstrated
cardiovascular and renal benefits. Multiple cardiovascular outcomes trials have
shown that certain GLP-1 RAs reduce the risk of major adverse cardiovascular
events, including cardiovascular death, myocardial infarction, and stroke, in
patients with T2DM and a high cardiovascular risk profile. These agents may
also slow the progression of chronic kidney disease and reduce the risk of
end-stage renal disease.

Comments
Post a Comment